Advertisement

Topics

BeiGene (Beijing), Co., Ltd. Company Profile

09:32 EDT 25th September 2018 | BioPortfolio

BeiGene is an innovative Chinese oncology R&D company focusing on discovering, developing and commercializing targeted and immune-oncology therapeutics. With a team of 150 scientists and staff, its pipeline is comprised of novel oral small molecules and monoclonal antibodies for cancer. BeiGene Ltd. is a Cayman Islands exempted company that is an investor in and collaborator with BeiGene (Beijing), Co. Ltd. For more information, please visit our website at www.beigene.com.


News Articles [311 Associated News Articles listed on BioPortfolio]

BeiGene and SpringWorks to Pair RAF and MEK Inhibitors in Solid Tumor Combo

BeiGene, a Beijing novel oncology company, will collaborate with New York's SpringWorks Therapeutics, combining BeiGene’s RAF inhibitor with SpringWorks' MEK inhibitor to treat patients with adv...

BeiGene Sets Price for Honk Kong IPO, Rakes in Almost $1 Billion

BeiGene, a biotech company based in Beijing, China and Cambridge, Massachusetts, announced it priced its initial public offering (IPO) on the Hong Kong stock exchange.

BeiGene Raised $900 Million in Hong Kong Debut Offering

BeiGene, a Beijing oncology company, hopes to raise $1 billion in a debut offering on the Hong Kong stock exchange. The company is already listed on NASDAQ in the US. BeiGene has five drug candidates ...

BeiGene Accepting Bids from Investors for $1 Billion Hong Kong IPO

BeiGene, a Beijing oncology company, hopes to raise $1 billion in a debut offering on the Hong Kong stock exchange. The company is already listed on NASDAQ in the US. BeiGene has five drug candidates ...

BeiGene Starts China Phase III Trial of PD-1 Drug in Squamous NSCLC

BeiGene, a Beijing oncology biopharma, has dosed the first patient in a China Phase III trial of its PD-1 antibody as a first-line treatment for lung cancer. According to BeiGene's count, the trial is...

BeiGene Reports Positive PD-1 Data; Plans China NDA Filing This Year

Beijing's BeiGene reported positive top-line results from a China pivotal Phase II trial of its PD-1 candidate in patients with classical Hodgkin's lymphoma. The drug produced a 73% overall response a...

BeiGene Starts China Trial of PARP Inhibitor in Ovarian Cancer Patients

BeiGene, a Beijing oncology company, has enrolled the first patient in a China Phase III trial of pamiparib (BGB-290), a PARP inhibitor, in patients with platinum-sensitive recurrent ovarian cancer. T...

BeiGene, SpringWorks to Study Combination Therapy for Advanced Solid Tumors

BeiGene’s RAF dimer inhibitor lifirafenib (BGB-283) and SpringWorks Therapeutics’ MEK inhibitor, PD-0325901 will be studied as a combination therapy for patients with advanced solid tumors in a tr...

Drugs and Medications [0 Results]

None

PubMed Articles [116 Associated PubMed Articles listed on BioPortfolio]

Particle Size Distribution and Human Health Risk Assessment of Heavy Metals in Atmospheric Particles from Beijing and Xinxiang During Summer.

Under a condition of good air quality (AQI:55-90, PM:37-97 μg·m, PM:17-76 μg·m), six groups of 54 samples were collected using an Andersen cascade impactor from both the indoor and outdoor station...

Self-rated depression and eye diseases: The Beijing Eye Study.

To assess the prevalence of depression in the general population of Beijing and its association with ocular diseases.

Chemical Characteristics and Sources of Heavy Metals in Fine Particles in Beijing in 2011-2012.

In order to investigate the chemical characteristics and sources of atmospheric heavy metals, PM samples were collected every three days during the summer of 2011 and summer of 2012. The samples were ...

Using big data from air quality monitors to evaluate indoor PM exposure in buildings: Case study in Beijing.

Due to time- and expense- consuming of conventional indoor PM (particulate matter with aerodynamic diameter of less than 2.5 μm) sampling, the sample size in previous studies was generally small, w...

Insight into multidrug-resistant Beijing genotype Mycobacterium tuberculosis isolates in Myanmar.

Myanmar is a WHO high tuberculosis (TB) burden country with a high multidrug-resistant (MDR)-TB burden. Significantly a high prevalence of the Beijing genotype of Mycobacterium tuberculosis (MTB) amon...

Clinical Trials [52 Associated Clinical Trials listed on BioPortfolio]

Beijing Indoor Air Health Intervention Study

The objective of this study is to investigate the cardiopulmonary health benefits from indoor air purification among school students in Beijing.

Beijing Indoor Air Purifier Intervention Study

This study aimed to assess the impact of air filtration on indoor air quality and cardio-pulmonary health in residents living in high outdoor pollution settings in Beijing.

Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in China

Anti-NMDA receptor encephalitis is the most common curable non-infectious autoimmune encephalitis,but because of the lack of recognition in the clinic, usually been misdiagnosed as other...

Beijing Hospital Atherosclerosis Study

The Beijing Hospital Atherosclerosis Study (BHAS) is a prospective, single-center, observational cohort study performed at the Beijing Hospital in Beijing, China. Subjects enrolled in this...

Trends of the Pre-hospital Emergency Care Spectrum in Beijing From 2005 to 2014: A Retrospective Analysis

This was a retrospective analysis of a cohort of all emergency care patients in Beijing from January 2005 to December 2014. This aim of this study was to analyze the trends in pre-hospital...

Companies [70 Associated Companies listed on BioPortfolio]

BeiGene (Beijing), Co., Ltd.

BeiGene is an innovative Chinese oncology R&D company focusing on discovering, developing and commercializing targeted and immune-oncology therapeutics. With a team of 150 scienti...

BeiGene Ltd.

BeiGene is an innovative, clinical-stage Chinese oncology R&D company focused on discovering, developing and commercializing targeted and immune-oncology therapeutics through a no...

BeiGene, Ltd.

BeiGene is a Chinese life sciences biotechnology company based in the Zhongguancun Life Science Park in Beijing that is focused on discovering and developing innovative oncology d...

Beijing Med-Pharm Corp

Beijing Med-Pharm offers an end-to-end solution to U.S and western pharmaceutical companies wishing to sell their products in China. We offer sales and marketing services throughout China and can help...

Celgene Corporation and BeiGene, Ltd.

More Information about "BeiGene (Beijing), Co., Ltd." on BioPortfolio

We have published hundreds of BeiGene (Beijing), Co., Ltd. news stories on BioPortfolio along with dozens of BeiGene (Beijing), Co., Ltd. Clinical Trials and PubMed Articles about BeiGene (Beijing), Co., Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BeiGene (Beijing), Co., Ltd. Companies in our database. You can also find out about relevant BeiGene (Beijing), Co., Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record